If it FtsZ

Taxis Pharmaceuticals Inc. has rescued a series of compounds in development limbo through a deal with Biota Pharmaceuticals Inc. (NASDAQ:BOTA), and used the molecules to create a preclinical first-in-class antibiotic that kills Gram-positive bacteria by disrupting the cell division machinery.

Now, Taxis is queuing the compound up for IND-enabling studies in September to treat Staphylococcus aureusinfections...